278 related articles for article (PubMed ID: 18166520)
1. Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal.
P V K; Palaian S; Ojha P; P R S
Pak J Pharm Sci; 2008 Jan; 21(1):51-6. PubMed ID: 18166520
[TBL] [Abstract][Full Text] [Related]
2. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in Nepal.
Mallik S; Palaian S; Ojha P; Mishra P
Pak J Pharm Sci; 2007 Jul; 20(3):214-8. PubMed ID: 17545106
[TBL] [Abstract][Full Text] [Related]
3. Study of adverse drug reactions caused by first line anti-tubercular drugs used in directly observed treatment, short course (DOTS) therapy in Western Nepal, Pokhara.
Chhetri AK; Saha A; Verma SC; Palaian S; Mishra P; Shankar PR
J Pak Med Assoc; 2008 Oct; 58(10):531-6. PubMed ID: 18998303
[TBL] [Abstract][Full Text] [Related]
4. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
[TBL] [Abstract][Full Text] [Related]
5. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital.
Jose J; Rao PG
Pharmacol Res; 2006 Sep; 54(3):226-33. PubMed ID: 16781163
[TBL] [Abstract][Full Text] [Related]
6. The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide.
Lin HS; Cheng CW; Lin MS; Chou YL; Chang PJ; Lin JC; Ye JJ
Clin Interv Aging; 2016; 11():299-306. PubMed ID: 27042029
[TBL] [Abstract][Full Text] [Related]
7. Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
Babalık A; Arda H; Bakırcı N; Ağca S; Oruç K; Kızıltaş S; Cetintaş G; Calışır HC
Tuberk Toraks; 2012; 60(2):136-44. PubMed ID: 22779934
[TBL] [Abstract][Full Text] [Related]
8. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
9. Pyrazinamide-induced granulomatous hepatitis.
Knobel B; Buyanowsky G; Dan M; Zaidel L
J Clin Gastroenterol; 1997 Jun; 24(4):264-6. PubMed ID: 9252856
[TBL] [Abstract][Full Text] [Related]
10. Profile of adverse drug reactions in drug resistant tuberculosis from Punjab.
Bhushan B; Chander R; Kajal NC; Ranga V; Gupta A; Bharti H
Indian J Tuberc; 2014 Oct; 61(4):318-24. PubMed ID: 25675695
[TBL] [Abstract][Full Text] [Related]
11. Assessment of protective role of polyherbal preparation, Livina, against anti-tubercular drug induced liver dysfunction.
Gulati K; Ray A; Vijayan VK
Indian J Exp Biol; 2010 Mar; 48(3):318-22. PubMed ID: 21046988
[TBL] [Abstract][Full Text] [Related]
12. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
Yee D; Valiquette C; Pelletier M; Parisien I; Rocher I; Menzies D
Am J Respir Crit Care Med; 2003 Jun; 167(11):1472-7. PubMed ID: 12569078
[TBL] [Abstract][Full Text] [Related]
13. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
[TBL] [Abstract][Full Text] [Related]
14. [A clinical investigation of seven patients with pulmonary tuberculosis who developed mixed liver injury during oral anti-tuberculosis treatment].
Nomi F; Hosaka K; Kurosawa T
Kekkaku; 2013 Sep; 88(9):647-51. PubMed ID: 24298690
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
16. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
Baniasadi S; Eftekhari P; Tabarsi P; Fahimi F; Raoufy MR; Masjedi MR; Velayati AA
Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1235-8. PubMed ID: 20461008
[TBL] [Abstract][Full Text] [Related]
18. [Hypothermia due to anti-tuberculosis drugs: first case].
Oualil H; Nejjari S; Bourkadi JE; Iraqi G
Rev Pneumol Clin; 2014 Oct; 70(5):298-301. PubMed ID: 24646781
[TBL] [Abstract][Full Text] [Related]
19. Adverse drug reactions experience in a teaching hospital in Jordan.
Alsbou M; Alzubiedi S; Alzobi H; Samhadanah NA; Alsaraireh Y; Alrawashdeh O; Aqel A; Al-Salem K
Int J Clin Pharm; 2015 Dec; 37(6):1188-93. PubMed ID: 26286340
[TBL] [Abstract][Full Text] [Related]
20. Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis.
Guo N; Marra F; Fitzgerald JM; Elwood RK; Marra CA
Eur Respir J; 2010 Jul; 36(1):206-8. PubMed ID: 20595167
[No Abstract] [Full Text] [Related]
[Next] [New Search]
